Opdyta 100mg injection (Nivolumab) | Apple pharmaceuticals

1
Apple Pharmaceuticals

• Is a fully licensed and regulated pharmacy, takes
  all precautions to strictly abide by the laws and
  regulations set forth in the dispensing of
  prescription medications. By placing the order
  for your prescription medicines, you acknowledge
  and accept the following terms regarding the
  purchase of any prescription medicines.

2
Nivolumab injection

• Opdyta 40mg

3
DESCRIPTION

• Opdyta 100mg is prescription drug which is used
  under supervision of doctor
• Opdyta 100mg belongs to human monoclonal antibody
  whichstops the interaction between PD-1 and its
  ligands, PD-L1 and PD-L2. Opdyta 100mg is an IgG4
  kappa immunoglobulin which has a calculated
  molecular mass of 146 kDa.
• It is expressed in a recombinant Chinese Hamster
  Ovary (CHO) cell line.
• Opdyta 100mg is also known as an immune
  checkpoint inhibitor. Sometimes these drugs are
  called targeted therapies because they target
  specific proteins (receptors) on the surface of
  cells.

4
INDICATION

• Opdyta 100mg is indicated for the treatment of
  patients having
• Melanoma
• Non-Small Cell Lung Cancer
• Kidney (Renal Cell) Cancer

MECHANISM
Binding of these ligands to the PD-1 receptor
occur on T cells, prohibits T cell multiplication
and cytokine production. Upregulation of the PD-1
ligands occurs in some tumor and signallingvia
this pathway can provide to prohibition of active
T-cell immune surveillance of tumor. Nivolumab
belongs to human immunoglobulin G4 (IgG4)
monoclonal antibody which binds to the PD-1
receptor and stops its interaction with PD-L1 and
PD-L2, releasing PD-1 pathway-mediated prevention
of the immune response, containing the anti-tumor
immune response, resulting in reduced tumor
growth.
5
DOSAGE

• Opdyta recommended dosage for unresectable or
  metastatic melanoma
• As single agent is either 240mg every 2 weeks or
  480mg every 4 weeks given as IV infusion over 30
  minutes until disease progression or unacceptable
  toxicity
• With ipilimumab
• The recommended dose of Opdyta is 1mg/kg
  administrated as an intravenous infusion over 30
  minutes, followed by ipilimumab 3mg/kg given as
  IV over 90 minutes on the same day. Duration 3
  weeks of max 4 doses, after completing
  combination dose continue the single agent
  treatment
• For adjuvant treatment of melanoma
• As single agent is either 240mg every 2 weeks or
  480mg every 4 weeks given as IV infusion over 30
  minutes until disease progression or unacceptable
  toxicity for up to 1 year.
• For Non-small cell lung cancer
• As single agent is either 240mg every 2 weeks or
  480mg every 4 weeks given as IV infusion over 30
  minutes until disease progression or unacceptable
  toxicity.
• For small cell lung cancer
• As single agent is either 240mg every 2 weeks
  given as IV infusion over 30 minutes until
  disease progression or unacceptable toxicity for
  up to 1 year.

6
PREGNANCY

• There are no available human data informing the
  drug-associated risk. Advise pregnant women of
  the potential risk to a foetus.

LACTATION
Opdyta 100mg Excretion in human breast milk is
not known advise women to discontinue
breastfeeding during treatment
7
CONTACT US
CALL
91-9987711567
EMAIL ID
applepharamaceutical_at_gmail.com
ADDRESS
Apartment No.304 A Wing, Shiva Shakthi chs
ltd, JP Road, Near Apna Bazar,Andheri(West),Mum
bai - 400058.Maharashtra.